GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

August 1, 2029

Study Completion Date

August 1, 2029

Conditions
Dementia, MildMild Cognitive ImpairmentType 2 Diabetes
Interventions
DRUG

Mazdutide

Mazdutide injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.

DRUG

Placebo

Placebo injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.

Trial Locations (7)

200040

Department of Endocrinology, Huadong Hospital Affiliated to Fudan University, Shanghai

200080

Department of Endocrinology, Shanghai General Hospital, Shanghai

210000

Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing

210008

Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing

410008

Department of Endocrinology, Xiangya Hospital of Central South University, Changsha

Unknown

Department of Endocrinology, Changzhou No.2 People's Hospital, Changzhou

Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing

All Listed Sponsors
collaborator

Nanjing First Hospital, Nanjing Medical University

OTHER

collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Huadong Hospital

OTHER

collaborator

Jiangsu Province Hospital of Traditional Chinese Medicine

OTHER

collaborator

Changzhou No.2 People's Hospital

OTHER

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER